Synthetic vitality

Why Versant, MPM chose Repare as their $68M synthetic lethality play

Versant Ventures and MPM Capital backed Repare Therapeutics Inc. with 2017’s largest series A round to get the synthetic lethality play to clinical proof of concept and possibly an exit.

Repare emerged from stealth mode on June 22

Read the full 384 word article

User Sign In